New Delhi, Aug. 5 -- Eris Lifesciences is gearing up to take advantage of India's booming diabetes-obesity market. The Ahmedabad-based drugmaker stands to gain in the country's human insulin market as innovator Novo Nordisk vacates, and it is betting on its insulin platform to grab a significant share in the anti-obesity market.

"We have a very successful insulin business with close to 10% market share in the country now. And any company that sells insulin well has been able to do GLP-1 very well," CEO Krishnakumar Vaidyanathan toldMintin an interview.

Danish drugmaker Novo Nordisk, which is the innovator of blockbuster anti-obesity drugs Ozempic and Wegovy, is also a market leader in insulin, with an over 50% market share in India. The...